CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel
Commercial payers pay $2129 on average nationally for this procedure.
CPT code 81412 describes a genomic sequence analysis panel performed on a patient specimen to evaluate genetic sequences of at least nine genes associated with disorders clustered in people of Ashkenazi Jewish descent; this service is a targeted hereditary genetic testing panel typically performed as a laboratory service in a clinical molecular genetics or reference laboratory setting and involves sequencing and analysis of multiple genes relevant to Ashkenazi Jewish–associated inherited disorders.
Customize your policy alerts
Sign up for cpt 81412 policy alerts
Get alerted when payer policies referencing 81412 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 81412 center on a BUCA average of $2,129.20 as a benchmark for aggregated commercial contracts. Blue Cross Blue Shield shows the highest dispersion with an interquartile range (P75–P25) of $1,107.00 ($2,861.80 − $1,754.80), indicating wider variability across contract rates. Cigna also exhibits substantial spread with an IQR of $1,749.40 ($2,986.70 − $1,237.30), while UnitedHealth Group’s IQR is $1,201.10 ($2,229.50 − $1,028.40). Aetna is the tightest among these payers with an IQR of $1,428.00 ($1,983.00 − $508.00), though its minimum of $0 suggests outliers.
Comparatively, BUCA’s commercial average sits near the higher-middle of payer means at $2,129.20, providing a useful cross-payer reference point. Blue Cross Blue Shield’s large max of $6,904.90 and Cigna’s max of $7,345.40 further highlight upper-tail variability that contributes to broader market dispersion, while UnitedHealth Group and Aetna show more moderate upper ranges relative to those peaks.